Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5441976 | 0.75 | KDM4E (0.34) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5447008 | 0.72 | TP53 (0.33) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5441931 | 0.71 | KDM4E (0.34) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL6738439 | 0.70 | KDM4E (0.34) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5438623 | 0.67 | CTSK (0.38) | KDM4EALDH1A1 | |
| SCHEMBL5443363 | 0.67 | CTSK (0.38) | KDM4EALDH1A1 | |
| SCHEMBL5438721 | 0.67 | CTSK (0.38) | KDM4EALDH1A1 | |
| SCHEMBL6697355 | 0.67 | — | — | |
| SCHEMBL5440671 | 0.66 | MMP1 (0.36) | KDM4EALDH1A1 | |
| SCHEMBL5440806 | 0.66 | PARP1 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135386-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-14 | — | — | US | claimed |
| US-20070135386-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-14 | — | — | US | disclosed |
| US-7196099-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135386-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | CTSS, CTSB, CTSE | KDM4E 4317/4885ALDH1A1 3814/4885FABP4 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.